Potential role of PI3K inhibitors in the treatment of breast cancer

Future Oncology

Volumn 6, Issue 8, 2010, Pages 1251-1263

  Carvalho, Sílvia ^a,b   Schmitt, Fernando ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

breast cancer; p110 ; p110 ; PI3K; PI3K inhibitor

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BGT 226; BKM 120; GSK 1059615; ISOPROTEIN; LETROZOLE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG; XL 147; XL 765;

BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL METABOLISM; CELL MOTILITY; CELL SURVIVAL; CLINICAL TRIAL; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE SILENCING; HUMAN; LYMPHOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; FEMALE; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 77956329400     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.97     Document Type: Review

References (143)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
2. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR: Molecular evolution of breast cancer. J. Pathol. 205(2), 248-254 (2005).
3. Reis-Filho JS, Lakhani SR: Breast cancer special types: why bother? J. Pathol. 216(4), 394-398 (2008).
4. Elston CW, Ellis IO, Pinder SE: Pathological prognostic factors in breast cancer. Crit. Rev. Oncol. Hematol. 31(3), 209-223 (1999).
5. Perou CM, Sorlie T, Eisen MB et al.: Molecular portraits of human breast tumours. Nature 406(6797), 747-752 (2000).
6. Sorlie T, Perou CM, Tibshirani R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001).
7. Sorlie T, Tibshirani R, Parker J et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100(14), 8418-8423 (2003).
8. Hu Z, Fan C, Oh DS et al.: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7, 96 (2006).
9. Reis-Filho JS, Tutt AN: Triple negative tumours: a critical review. Histopathology 52(1), 108-118 (2008).
10. Nagata Y, Lan KH, Zhou X et al.: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2), 117-127 (2004).
11. Kirkegaard T, Witton CJ, Mcglynn LM et al.: AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J. Pathol. 207(2), 139-146 (2005).
12. Normanno N, Morabito A, De Luca A et al.: Target-based therapies in breast cancer: current status and future perspectives. Endocr. Relat. Cancer 16(3), 675-702 (2009).
13. Klein S, Levitzki A: Targeting the EGFR and the PKB pathway in cancer. Curr. Opin. Cell Biol. 21(2), 185-193 (2009).
14. Bader AG, Kang S, Zhao L, Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 5(12), 921-929 (2005).
15. Crowder RJ, Phommaly C, Tao Y et al.: PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res. 69(9), 3955-3962 (2009).
16. Cully M, You H, Levine AJ, Mak TW: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6(3), 184-192 (2006).
17. Engelman JA, Luo J, Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7(8), 606-619 (2006).
18. Garcia-Echeverria C, Sellers WR: Drug discovery approaches targeting the PI3K/ AKT pathway in cancer. Oncogene 27(41), 5511-5526 (2008).
19. Khan S, Kumagai T, Vora J et al.: PTEN promoter is methylated in a proportion of invasive breast cancers. Int. J. Cancer 112(3), 407-410 (2004).
20. Racz A, Brass N, Heckel D, Pahl S, Remberger K, Meese E: Expression analysis of genes at 3q26-q27 involved in frequent amplification in squamous cell lung carcinoma. Eur. J. Cancer 35(4), 641-646 (1999).
21. Wymann MP, Marone R: Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr. Opin. Cell Biol. 17(2), 141-149 (2005).
22. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296(5573), 1655-1657 (2002).
23. Wymann MP, Zvelebil M, Laffargue M: Phosphoinositide 3-kinase signalling - which way to target? Trends Pharmacol. Sci. 24(7), 366-376 (2003).
24. Gaidarov I, Smith ME, Domin J, Keen JH: The class II phosphoinositide 3-kinase c2a is activated by clathrin and regulates clathrin-mediated membrane trafficking. Mol. Cell 7(2), 443-449 (2001).
25. Backer JM: The regulation and function of class III PI3Ks: novel roles for VPS34. Biochem. J. 410(1), 1-17 (2008).
26. Byfield MP, Murray JT, Backer JM: HVPS34 is a nutrient-regulated lipid kinase required for activation of p70 s6 kinase. J. Biol. Chem. 280(38), 33076-33082 (2005).
27. Nobukuni T, Joaquin M, Roccio M et al.: Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3oh-kinase. Proc. Natl Acad. Sci. USA 102(40), 14238-14243 (2005).
28. Petiot A, Ogier-Denis E, Blommaart EF, Meijer AJ, Codogno P: Distinct classes of phosphatidylinositol 3 -kinases are involved in signaling pathways that control macroautophagy in ht-29 Cells. J. Biol. Chem. 275(2), 992-998 (2000).
29. Kihara A, Noda T, Ishihara N, Ohsumi Y: Two distinct vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carboxypeptidase y sorting in saccharomyces cerevisiae. J. Cell Biol. 152(3), 519-530 (2001).
30. Yuan TL, Cantley LC: PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41), 5497-5510 (2008).
31. Zhao L, Vogt PK: Class I PI3K in oncogenic cellular transformation. Oncogene 27(41), 5486-5496 (2008).
32. Skolnik EY, Margolis B, Mohammadi M et al.: Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/ cloning of target proteins for receptor tyrosine kinases. Cell 65(1), 83-90 (1991).
33. Guillermet-Guibert J, Bjorklof K, Salpekar A et al.: The p110b isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110g. Proc. Natl Acad. Sci. USA 105(24), 8292-8297 (2008).
34. Songyang Z, Shoelson SE, Chaudhuri M et al.: Sh2 domains recognize specific phosphopeptide sequences. Cell 72(5), 767-778 (1993).
35. Carpenter CL, Auger KR, Chanudhuri M et al.: Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the Sh2 domains of the 85-kda subunit. J. Biol. Chem. 268(13), 9478-9483 (1993).
36. Yu J, Zhang Y, Mcilroy J, Rordorf-Nikolic T, Orr GA, Backer JM: Regulation of the p85/ p110 phosphatidylinositol 3 -kinase: stabilization and inhibition of the p110a catalytic subunit by the p85 regulatory subunit. Mol. Cell Biol. 18(3), 1379-1387 (1998).
37. Yu J, Wjasow C, Backer JM: Regulation of the p85/p110a phosphatidylinositol 3́-kinase. Distinct roles for the n-terminal and c-terminal Sh2 domains. J. Biol. Chem. 273(46), 30199-30203 (1998).
38. Shaw RJ, Cantley LC: Ras, pi(3)k and mTOR signalling controls tumour cell growth. Nature 441(7092), 424-430 (2006).
39. Cantley LC, Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl Acad. Sci. USA 96(8), 4240-4245 (1999).
40. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of AKT/PKB by the rictor-mTOR complex. Science 307(5712), 1098-1101 (2005).
41. Inoki K, Li Y, Zhu T, Wu J, Guan KL: TSC2 is phosphorylated and inhibited by AKT and suppresses mTOR signalling. Nat. Cell Biol. 4(9), 648-657 (2002).
42. Myers MP, Pass I, Batty IH et al.: The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl Acad. Sci. USA 95(23), 13513-13518 (1998).
43. Li J, Yen C, Liaw D et al.: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(5308), 1943-1947 (1997).
44. Naylor TL, Greshock J, Wang Y et al.: High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res. 7(6), R1186-R1198 (2005).
45. Garcia JM, Silva J, Pena C et al.: Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 41(2), 117-124 (2004).
46. Samuels Y, Wang Z, Bardelli A et al.: High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670), 554 (2004).
47. Kim MS, Jeong EG, Yoo NJ, Lee SH: Mutational analysis of oncogenic AKT e17k mutation in common solid cancers and acute leukaemias. Br. J. Cancer 98(9), 1533-1535 (2008).
48. Carpten JD, Faber AL, Horn C et al.: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448(7152), 439-444 (2007).
49. Wu G, Xing M, Mambo E et al.: Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res. 7(5), R609-616 (2005).
50. Bellacosa A, De Feo D, Godwin AK et al.: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64(4), 280-285 (1995).
51. Saal LH, Holm K, Maurer M et al.: PIK3CA mutations correlate with hormone receptors, node metastasis, and erbb2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65(7), 2554-2559 (2005).
52. Buttitta F, Felicioni L, Barassi F et al.: PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J. Pathol. 208(3), 350-355 (2006).
53. Li SY, Rong M, Grieu F, Iacopetta B: PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res.Treat. 96(1), 91-95 (2006).
54. Lerma E, Catasus L, Gallardo A et al.: Exon 20 PIK3CA mutations decreases survival in aggressive (her-2 positive) breast carcinomas. Virchows Arch. 453(2), 133-139 (2008).
55. Kalinsky K, Jacks LM, Heguy A et al.: PIK3CA mutation associates with improved outcome in breast cancer. Clin. Cancer Res. 15(16), 5049-5059 (2009).
56. Hynes NE, Lane HA: Erbb receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 5(5), 341-354 (2005).
57. Moasser MM, Basso A, Averbuch SD, Rosen N: The tyrosine kinase inhibitor zd1839 ("iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 61(19), 7184-7188 (2001).
58. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, 3rd, Hynes NE: The erbb2/erbb3 heterodimer functions as an oncogenic unit: Erbb2 requires erbb3 to drive breast tumor cell proliferation. Proc. Natl Acad. Sci. USA 100(15), 8933-8938 (2003).
59. Vogt PK, Bader AG, Kang S: PI 3-kinases: Hidden potentials revealed. Cell Cycle 5(9), 946-949 (2006).
60. Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9(8), 550-562 (2009).
61. Sawyer C, Sturge J, Bennett DC et al.: Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110d. Cancer Res. 63(7), 1667-1675 (2003).
62. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL: Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110a subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274(16), 10963-10968 (1999).
63. Bi L, Okabe I, Bernard DJ, Nussbaum RL: Early embryonic lethality in mice deficient in the p110b catalytic subunit of PI 3-kinase. Mamm. Genome 13(3), 169-172 (2002).
64. Parsons DW, Jones S, Zhang X et al.: An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897), 1807-1812 (2008).
65. Yamamoto H, Shigematsu H, Nomura M et al.: PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 68(17), 6913-6921 (2008).
66. Thomas RK, Baker AC, Debiasi RM et al.: High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39(3), 347-351 (2007).
67. Shayesteh L, Lu Y, Kuo WL et al.: PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21(1), 99-102 (1999).
68. Campbell IG, Russell SE, Choong DY et al.: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64(21), 7678-7681 (2004).
69. Samuels Y, Diaz LA Jr, Schmidt-Kittler O et al.: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6), 561-573 (2005).
70. Kang S, Bader AG, Vogt PK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl Acad. Sci. USA 102(3), 802-807 (2005).
71. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM: The oncogenic properties of mutant p110a and p110b phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc. Natl Acad. Sci. USA 102(51), 18443-18448 (2005).
72. Isakoff SJ, Engelman JA, Irie HY et al.: Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 65(23), 10992-11000 (2005).
73. Bader AG, Kang S, Vogt PK: Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl Acad. Sci. USA 103(5), 1475-1479 (2006).
74. Zhao L, Vogt PK: Helical domain and kinase domain mutations in p110a of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl Acad. Sci. USA 105(7), 2652-2657 (2008).
75. Miled N, Yan Y, Hon WC et al.: Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317(5835), 239-242 (2007).
76. Huang CH, Mandelker D, Schmidt-Kittler O et al.: The structure of a human p110a/p85a complex elucidates the effects of oncogenic PI3Ka mutations. Science 318(5857), 1744-1748 (2007).
77. Huang CH, Mandelker D, Gabelli SB, Amzel LM: Insights into the oncogenic effects of PIK3CA mutations from the structure of p110a/p85a. Cell Cycle 7(9), 1151-1156 (2008).
78. Mandelker D, Gabelli SB, Schmidt-Kittler O et al.: A frequent kinase domain mutation that changes the interaction between PI3Ka and the membrane. Proc. Natl Acad. Sci. USA 106(40), 16996-17001 (2009).
79. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S: Clinicopathologic analysis of breast cancers with PIK3CA mutations in japanese women. Clin. Cancer Res. 13(2 Pt 1), 408-414 (2007).
80. Perez-Tenorio G, Alkhori L, Olsson B et al.: PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin. Cancer Res. 13(12), 3577-3584 (2007).
81. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A et al.: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 68(15), 6084-6091 (2008).
82. Bachman KE, Argani P, Samuels Y et al.: The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 3(8), 772-775 (2004).
83. Levine DA, Bogomolniy F, Yee CJ et al.: Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin. Cancer Res. 11(8), 2875-2878 (2005).
84. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M: Phosphatidylinositol-3-OH kinase or ras pathway mutations in human breast cancer cell lines. Mol. Cancer Res. 5(2), 195-201 (2007).
85. Fujita T, Doihara H, Kawasaki K et al.: PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of erbb2-overexpressing breast cancer. Br. J. Cancer 94(2), 247-252 (2006).
86. Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H: Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2- amplified breast cancer cell lines. Ann. Oncol. 21(2), 255-262 (2010).
87. Depowski PL, Rosenthal SI, Ross JS: Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod. Pathol. 14(7), 672-676 (2001).
88. Vasudevan KM, Barbie DA, Davies MA et al.: AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16(1), 21-32 (2009).
89. Jia S, Roberts TM, Zhao JJ: Should individual PI3 kinase isoforms be targeted in cancer? Curr. Opin. Cell Biol. 21(2), 199-208 (2009).
90. Kang S, Denley A, Vanhaesebroeck B, Vogt PK: Oncogenic transformation induced by the p110b, -g, and -d isoforms of class I phosphoinositide 3-kinase. Proc. Natl Acad. Sci. USA 103(5), 1289-1294 (2006).
91. Jia S, Liu Z, Zhang S et al.: Essential roles of pi(3)k-p110b in cell growth, metabolism and tumorigenesis. Nature 454(7205), 776-779 (2008).
92. Wee S, Wiederschain D, Maira SM et al.: PTEN-deficient cancers depend on PIK3CB. Proc. Natl Acad. Sci. USA 105(35), 13057-13062 (2008).
93. Ciraolo E, Iezzi M, Marone R et al.: Phosphoinositide 3-kinase p110b activity: key role in metabolism and mammary gland cancer but not development. Sci. Signal 1(36), RA3 (2008).
94. Carvalho S, Milanezi F, Costa JL, Amendoeira I, Schmitt F: PIKing the right isoform: the emergent role of the p110b subunit in breast cancer. Virchows Arch. 456(3), 235-243 (2010).
95. Workman P, Clarke PA, Guillard S, Raynaud FI: Drugging the PI3 kinome. Nat. Biotechnol. 24(7), 794-796 (2006).
96. Bain J, Plater L, Elliott M et al.: The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408(3), 297-315 (2007).
97. Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351(Pt 1), 95-105 (2000).
98. Knight ZA, Shokat KM: Chemically targeting the PI3K family. Biochem. Soc. Trans. 35(Pt 2), 245-249 (2007).
99. Baggiolini M, Dewald B, Schnyder J, Ruch W, Cooper PH, Payne TG: Inhibition of the phagocytosis-induced respiratory burst by the fungal metabolite wortmannin and some analogues. Exp. Cell Res. 169(2), 408-418 (1987).
100. Arcaro A, Wymann MP: Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem. J. 296 ( Pt 2), 297-301 (1993).
101. Vlahos CJ, Matter WF, Hui KY, Brown RF: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4h-1- benzopyran-4-one (ly294002). J. Biol. Chem. 269(7), 5241-5248 (1994).
102. Yap TA, Garrett MD, Walton MI, Raynaud F, De Bono JS, Workman P: Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 8(4), 393-412 (2008).
103. Yu K, Lucas J, Zhu T et al.: Pwt-458, a novel pegylated-17- hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol. Ther. 4(5), 538-545 (2005).
104. Ihle NT, Paine-Murrieta G, Berggren MI et al.: The phosphatidylinositol- 3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in a-549 human non-small cell lung cancer xenografts. Mol. Cancer Ther. 4(9), 1349-1357 (2005).
105. Howes AL, Chiang GG, Lang ES et al.: The phosphatidylinositol 3-kinase inhibitor, px-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol. Cancer Ther. 6(9), 2505-2514 (2007).
106. Garlich JR, De P, Dey N et al.: A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 68(1), 206-215 (2008).
107. Ozbay T, Durden DL, Liu T, O regan RM, Nahta R: In vitro evaluation of pan-PI3- kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. Cancer Chemother. Pharmacol. 65(4), 697-706 (2010)
108. Hayakawa M, Kaizawa H, Moritomo H et al.: Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110a inhibitors. Bioorg. Med. Chem. 14(20), 6847-6858 (2006).
109. Knight ZA, Gonzalez B, Feldman ME et al.: A pharmacological map of the PI3-k family defines a role for p110a in insulin signaling. Cell 125(4), 733-747 (2006).
110. Fan QW, Knight ZA, Goldenberg DD et al.: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9(5), 341-349 (2006).
111. Hayakawa M, Kaizawa H, Kawaguchi K et al.: Synthesis and biological evaluation of imidazo[1,2-a pyridine derivatives as novel PI3 kinase p110a inhibitors. Bioorg. Med. Chem. 15(1), 403-412 (2007).
112. Hayakawa M, Kawaguchi K, Kaizawa H et al.: Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a] pyridines as novel PI3 kinase p110a inhibitors. Bioorg. Med. Chem. 15(17), 5837-5844 (2007).
113. Hayakawa M, Kaizawa H, Moritomo H et al.: Synthesis and biological evaluation of pyrido[3 ,2 :4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110a inhibitors. Bioorg. Med. Chem. Lett. 17(9), 2438-2442 (2007).
114. Raynaud FI, Eccles S, Clarke PA et al.: Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res.67(12), 5840-5850 (2007).
115. Guillard S, Clarke PA, Te Poele R et al.: Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell Cycle 8(3), 443-453 (2009).
116. Raynaud FI, Eccles SA, Patel S et al.: Biological properties of potent inhibitors of class i phosphatidylinositide 3-kinases: From PI-103 through PI-540, PI-620 to the oral agent gdc-0941. Mol. Cancer Ther. 8(7), 1725-1738 (2009).
117. Folkes AJ, Ahmadi K, Alderton WK et al.: The identification of 2-(1h-indazol-4-yl)-6- (4-methanesulfonyl-piperazin-1-ylmethyl)-4- morpholin -4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 51(18), 5522-5532 (2008).
118. Junttila TT, Akita RW, Parsons K et al.: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor gdc-0941. Cancer Cell 15(5), 429-440 (2009).
119. Yao E, Zhou W, Lee-Hoeflich ST et al.: Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin. Cancer Res.15(12), 4147-4156 (2009).
120. Foster PG: Potentiating the antitumor effects of chemotherapy with selective PI3K inhibitor XL147. Presented at: 19th AACR-NCI-EORTC Meeting CA, USA, 22-26 October 2007.
121. Shapiro GI, Edelman G, Calvo E, Aggarwal SK, Laird AD: Targeting aberrant PI3K pathway signaling with xl147, a potent, selective, and orally bioavailable PI3K inhibitor. Presented at: 19th AACR-NCI-EORTC Meeting CA, USA, 22-26 October 2007 (Abstract C205).
122. Laird D: Xl765 targets tumor growth, survival, and angiogenesis in preclinical models by dual inhibiton of PI3K and mTOR. Presented at: 19th AACR-NCI-EORTC Meeting CA, USA, 22-26 October 2007 (Abstract B250).
123. Patnaik A, Lorusso PM, Tabernero J, Laird AD, Aggarwal SK, Papadopoulos KP: Biomarker development of XL765, a potent and selective oral dual inhibitor of PI3K and mTOR currently being administrated to patients in a Phase I clinical trial. Presented at: 19th AACR-NCI-EORTC Meeting CA, USA, 22-26 October 2007 (Abstract B265).
124. Maira SM, Stauffer F, Brueggen J et al.: Identification and characterization of nvp-bez235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7(7), 1851-1863 (2008).
125. Engelman JA, Chen L, Tan X et al.: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14(12), 1351-1356 (2008).
126. Serra V, Markman B, Scaltriti M et al.: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68(19), 8022-8030 (2008).
127. Sun SY, Rosenberg LM, Wang X et al.: Activation of AKT and eif4e survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65(16), 7052-7058 (2005).
128. O Reilly KE, Rojo F, She QB et al.: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT. Cancer Res. 66(3), 1500-1508 (2006).
129. Ward SG, Finan P: Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr. Opin. Pharmacol. 3(4), 426-434 (2003).
130. Jackson SP, Schoenwaelder SM, Goncalves I et al.: Pi 3-kinase p110b: a new target for antithrombotic therapy. Nat. Med. 11(5), 507-514 (2005).
131. Rommel C, Camps M, Ji H: PI3K d and PI3K g: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 7(3), 191-201 (2007).
132. Park SJ, Min KH, Lee YC: Phosphoinositide 3-kinase d inhibitor as a novel therapeutic agent in asthma. Respirology 13(6), 764-771 (2008).
133. Ameriks MK, Venable JD: Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) d and g. Curr. Top. Med. Chem. 9(8), 738-753 (2009).
134. Walker EH, Perisic O, Ried C, Stephens L, Williams RL: Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402(6759), 313-320 (1999).
135. Walker EH, Pacold ME, Perisic O et al.: Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, ly294002, quercetin, myricetin, and staurosporine. Mol. Cell. 6(4), 909-919 (2000).
136. Berndt A, Miller S, Williams O et al.: The p110 d structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat. Chem. Biol. 6(2), 117-124 (2010).
137. Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE: Essential role of phosphoinositide 3-kinase d in neutrophil directional movement. J. Immunol. 170(5), 2647-2654 (2003).
138. Knight ZA, Chiang GG, Alaimo PJ et al.: Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg. Med. Chem. 12(17), 4749-4759 (2004).
139. Torbett NE, Luna-Moran A, Knight ZA et al.: A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J. 415(1), 97-110 (2008).
140. Chen JS, Zhou LJ, Entin-Meer M et al.: Characterization of structurally distinct, isoform-selective phosphoinositide 3́-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol. Cancer Ther. 7(4), 841-850 (2008).
141. Baselga J, Semiglazov V, Van Dam P et al.: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 27(16), 2630-2637 (2009).
142. Berns K, Horlings HM, Hennessy BT et al.: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4), 395-402 (2007).
143. Eichhorn PJ, Gili M, Scaltriti M et al.: Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/ phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 68(22), 9221-9230 (2008).